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Abstract
Background: Hypertension is a major risk factor for cardiovascular disease (CVD). Despite advances in hypertension
prevention and treatment, the proportion of patients who are aware, treated and controlled is low, particularly in low-
income and middle-income countries (LMICs). We will evaluate an adapted version of a multilevel and multicomponent
hypertension control program in Guatemala, previously proven effective and feasible in Argentina. The program
components are: protocol-based hypertension treatment using a standardized algorithm; team-based collaborative care;
health provider education; health coaching sessions; home blood pressure monitoring; blood pressure audit; and feedback.
Methods: Using a hybrid type 2 effectiveness-implementation design, we will evaluate clinical and implementation
outcomes of the multicomponent program in Guatemala over an 18-month period. Through a cluster randomized trial, we
will randomly assign 18 health districts to the intervention arm and 18 to enhanced usual care across five departments,
enrolling 44 participants per health district and 1584 participants in total. The clinical outcomes are (1) the difference in the
proportion of patients with controlled hypertension (< 130/80mmHg) between the intervention and control groups at 18
months and (2) the net change in systolic and diastolic blood pressure from baseline to 18months. The context-enhanced
Reach, Efficacy, Adoption, Implementation, Maintenance (RE-AIM)/Practical Robust Implementation and Sustainability Model
(PRISM) framework will guide the evaluation of the implementation at the level of the patient, provider, and health system.
Using a mixed-methods approach, we will evaluate the following implementation outcomes: acceptability, adoption,
feasibility, fidelity, adaptation, reach, sustainability, and cost-effectiveness.
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Discussion: We will disseminate the study findings, and promote scale up and scale out of the program, if proven effective.
This study will generate urgently needed data on effective, adoptable, and sustainable interventions and implementation
strategies to improve hypertension control in Guatemala and other LMICs.
Trial registration: ClinicalTrials.gov: NCT03504124. Registered on 20 April 2018.
Keywords: Multicomponent program, Hypertension, Cardiovascular disease, Primary care, Health systems, Implementation
strategies, Implementation science, Low-income and middle-income countries, Guatemala, Non-communicable diseases
Background
Hypertension is the leading preventable risk factor for
cardiovascular disease (CVD), premature death and
disability worldwide [1]. It contributes to the burden
of cardiovascular disease and chronic kidney disease
worldwide, particularly in low-income and middle-
income countries (LMICs) [2, 3]. It is estimated that
31.1% of the adult population had hypertension in
2010, three quarters of whom were living in LMICs
[3]. While its prevalence is steady or decreasing in
high-income countries, it increased by 7.7% from
2000 to 2010 in LMICs [3, 4]. In Latin America,
hypertension is the most important risk factor for
coronary heart disease and stroke [5]. However, the
proportion of patients who are aware, treated and
controlled is low. A survey conducted in Guatemala
showed that the prevalence of hypertension in adults
older than 40 years is 41%, while only 61% are aware
of their condition and only half of those who are
aware usually take antihypertensive medications [6].
Despite the availability of evidence-based hyperten-
sion treatment guidelines, multiple barriers hinder
the appropriate management of hypertension in pri-
mary care settings. Hypertension guidelines recom-
mend antihypertensive medications and individualized
lifestyle changes, which include weight loss, physical
activity, reduced alcohol and sodium intake, and a
diet rich in fruits and vegetables and in low-fat dairy
products with reduced saturated and total fat (Diet-
ary Approaches to Stop Hypertension, DASH) [7–
12]. Our formative needs assessment documented
several limitations related to hypertension manage-
ment in Guatemala, including a limited health budget
for the treatment of non-communicable diseases,
fragmented governance and service delivery, inad-
equate training of the healthcare workforce, and
shortage of essential hypertensive medications and
basic equipment, particularly at frontline facilities
[13]. In addition, an overarching challenge is the
prioritization of infectious diseases and maternal and
child health over non-communicable diseases [13]. In
other countries, barriers for implementing hyperten-
sion treatment guidelines at the primary care level
include organizational-level obstacles, communication
problems between the primary and secondary levels
of care, multiple competing demands on physicians’
time, and lack of reimbursement for preventive coun-
seling [14, 15]. Many implementation strategies tar-
geting healthcare administration, facilities, providers,
and patients have been proven effective at improving
hypertension control. Specifically, these strategies in-
clude team-based care, health coaching sessions,
home-based blood pressure (BP) monitoring, clinical
decision support, BP audit and feedback, and training
of healthcare providers. Moreover, a combination of
strategies is more effective than individual ones [16].
This study is an implementation-effectiveness, hybrid,
type 2, cluster randomized control trial that will evaluate a
multilevel and multicomponent hypertension control pro-
gram within the Guatemalan primary care system [17].
Through a formative mixed-methods assessment and adap-
tation workshops, we have adapted the effective Hyperten-
sive Control Program in Argentina (HCPIA) and other
implementation strategies to the Guatemalan context [13].
The multicomponent program includes a protocol-based
hypertension treatment and five implementation strategies:
team-based collaborative care, health provider education,
health coaching sessions, home blood pressure monitoring,
and blood pressure audit and feedback. This program tar-
gets the first level (health posts) and second level (health
centers) of care in the public health system.
Methods and design
Setting
The Guatemalan public health system serves 70% of the
population and is organized in three levels of care [18].
The first, second, and third levels comprise health posts,
health centers, and hospitals, which serve the commu-
nity, municipal, and the regional level, respectively.
Health posts are staffed by auxiliary nurses, while health
centers are staffed by general physicians, professional
nurses, auxiliary nurses and, in some cases, psychologists
or social workers. Health posts and health centers are
responsible for providing promotional, preventative, and
primary care services. Health districts represent the
municipal administration. The three levels of care are
connected by referral networks with the goal of decen-
tralizing health services and increasing access to care.
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However, the vast majority of healthcare providers and
facilities are concentrated in urban areas, leaving rural
communities with limited access to health services [18].
We are conducting this study within the first (health
posts) and second (health centers) levels of care. With
approval from the Ministry of Health, we selected 36
health districts distributed in five departments: Baja Ver-
apaz (n = 4), Chiquimula (n = 10), Huehuetenango (n =
10), Sololá (n = 10), and Zacapa (n = 2). The study will
be implemented at the health center and 1–2 health
posts per health district, making a total of 36 health cen-
ters and 71 health posts (See Fig. 1).
The eligibility criteria for health districts are the following:
1. Having at least one health post with two or more
auxiliary nurses and basic infrastructure to store
clinical charts
2. Serving rural and semirural communities
3. Having at least one professional nurse or physician
per health district, responsible for supervising the
health post(s)
Aims
The overarching aim of this study is to evaluate the clinical
effectiveness and implementation outcomes of a hyperten-
sion control multicomponent program within the first and
second levels of care in Guatemala, compared to usual
care. Our main hypothesis is that the multicomponent
program will improve hypertension control among pa-
tients with uncontrolled hypertension treated in the public
healthcare system of Guatemala.
The co-primary objectives are:
1. To test if a multilevel and multicomponent
intervention program improves hypertension
control among Guatemalan hypertensive patients
over an 18-month period compared to usual care.
2. To evaluate the acceptability, adoption, feasibility,
fidelity, adaptation, reach, and sustainability of
implementing the intervention in the primary care
setting.
The secondary objective is
3. to evaluate the cost-effectiveness of the multilevel
and multicomponent intervention program, com-
pared to usual care.
Study design: implementation-effectiveness cluster
randomized controlled trial
We are conducting a hybrid type 2 effectiveness-
implementation, cluster randomized controlled trial
(cRCT). We have randomly assigned 18 health
districts (clusters) to the intervention arm and 18 to
enhanced usual care (control arm) across five depart-
ments. We will enroll 44 participants per health dis-
trict and 1584 participants in total. After selecting 36
eligible health districts, and before initiating partici-
pant recruitment, health districts were randomized
and stratified by department, using a computerized
random number generator. The trial flow chart is
shown in Fig. 2 and the Standard Protocol Items:
Recommendation for Interventional Trials (SPIRIT)
figure is shown in Fig. 3. The SPIRIT checklist is
provided in Additional file 1.
Study participants
The study follows minimum eligibility criteria to
evaluate the intervention in a real-world setting. Men
and women 40 years or older with uncontrolled
Fig. 1 Study sites: intervention and control health districts
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hypertension, and who meet the following eligibility
criteria will participate in the study:
 Have uncontrolled hypertension, which will be
ascertained by measuring BP at two screening
visits, scheduled 1–7 days apart from each other.
Participants with stage II hypertension (average
systolic BP ≥ 140 mmHg or diastolic BP ≥ 90
mmHg) are eligible. Participants with stage I
hypertension (average systolic BP 130–139 mmHg
or diastolic BP 80–89 mmHg) are eligible if they
meet at least one of the following characteristics:
(1) taking antihypertensive medications;
(2) history of cardiovascular disease (myocardial
infarction or stroke);
(3) estimated cardiovascular risk higher than 10% in
5 years (based on the NHANES I follow-up study
cardiovascular risk estimation) using a non-
invasive prediction indicator [19, 20].
 Live in a community served by one of the 71
participating health posts and willing to receive
hypertension care at the health post.
 Be willing to sign an informed consent form before
any study procedure is performed. For illiterate
patients, a witness who reads and understands the
consent will co-sign the informed consent form.
Individuals who have any of the following exclusion
criteria will not be eligible to participate in the study:
 Pregnant according to self-report
 Diagnosed end-stage renal disease or any chronic
terminal disease
 Bedridden
Fig. 2 Trial flow chart. BP, blood pressure
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 Planning to move from the study area within the
next 18 months
Participants are being recruited from participating
health posts and from the community in their catch-
ment area. Auxiliary nurses help study staff to
identify potential participants and implement the
intervention (see below), but do not participate in
any study measurement.
Multicomponent intervention
The study intervention is a multicomponent and multi-
level program to improve hypertension control over 18
months. The program is composed of one core interven-
tion and five evidence-based implementation strategies
(See Fig. 4), which are defined as methods to enhance
the adoption, implementation, and sustainment of the
core intervention [21]. The core intervention and imple-
mentation strategies were previously adapted to the rural
Guatemalan context by the study team and stakeholders
from the Ministry of Health and local communities [13].
Physicians and nurses working at intervention health
centers and auxiliary nurses working at health posts are
responsible for delivering the intervention.
Core intervention: protocol-based hypertension treatment
The study team and Ministry of Health officials designed a
standardized stepped-care hypertension treatment protocol
summarized in an algorithm, based on the American Heart
Association (AHA) Hypertension Guidelines 2017 and the
Guatemala Ministry of Health Healthcare Norms 2018 [22,
23]. After participants are enrolled in the study, health dis-
trict physicians, nurses, and auxiliary nurses will establish
an individualized treatment plan for the participant to reach
a BP target < 130/80mmHg, with a combination of anti-
hypertensive medications offered by the Ministry of Health:
hydrochlorothiazide, enalapril and losartan. The study team
provided educational materials and pocket cards summariz-
ing the hypertension treatment algorithm to healthcare
Fig. 3 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) figure
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providers and an electronic BP monitor (Omron HEM-
7121) to each health center and health post.
Implementation strategies
Team-based collaborative care
Teams of physicians, nurses, and auxiliary nurses from
health posts and health centers will work collaboratively
to establish a treatment plan for hypertensive patients.
After study enrollment, a physician or nurse will perform
a physical examination, confirm the hypertension diagno-
sis and select the initial anti-hypertensive medications fol-
lowing the standardized hypertension treatment protocol
described above. Auxiliary nurses from health posts (first
level of care) will be in charge of follow up and health
coaching sessions, and will coordinate and connect pa-
tients with physicians and nurses at the health center (sec-
ond level of care). The collaborative team will meet at
least monthly at the health center to discuss cases of un-
controlled hypertension or adverse events and make clin-
ical decisions following the standardized hypertension
treatment protocol. Usual care provided by the Ministry
of Health for patients with hypertension does not include
team-based collaborative care.
Health provider education
The study team provided an interactive 2-day workshop
for physicians, nurses and auxiliary nurses, during the sec-
ond semester of 2019. Training content included: BP
management using a stepped-care protocol-based hyper-
tension treatment; titration and adverse effects of anti-
hypertensive medications; team-based collaborative care;
and motivational interviewing skills to promote medica-
tion adherence and healthy lifestyle modifications during
health coaching sessions. One month after the training,
the study team conducted individualized field certifica-
tions on blood pressure measurement and health coaching
sessions with auxiliary nurses working in health posts.
Periodic training will be provided to newly hired providers
and as refreshers. Usual hypertensive care does not
Fig. 4 Multicomponent hypertension control program: core intervention and implementation strategies. HTN, hypertension; BP, blood pressure
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include training for healthcare providers about hyperten-
sive management.
Health coaching sessions
Auxiliary nurses conduct health coaching sessions focused
on promoting adherence to anti-hypertensive medications,
strategies to overcome treatment side effects and lifestyle
modifications: reaching or maintaining a healthy weight,
limiting sodium and alcohol intake, getting regular physical
activity, and adopting an eating plan based on the Dietary
Approaches to Stop Hypertension (DASH). Participants re-
ceive an educational flipchart adapted from the manual
“Healthy and Happy Heart” (Corazon Sano y Feliz), previ-
ously developed and piloted in Guatemala [24], and a card
to register BP measurements. Relatives will be encouraged
to participate in health coaching sessions. During the first 3
months of the intervention, health coaching sessions will
take place monthly during the first 3 months of the inter-
vention. If the patient meets the BP target, the frequency
will be reduced to every 3 months. Usual hypertensive care
does not include health coaching sessions.
Home blood pressure monitoring
After study enrollment, each patient receiving care at
one of the intervention health districts obtains an elec-
tronic home BP monitor that stores 30 readings with
date and time stamp (Omron HEM-7121). Auxiliary
nurses will teach patients and literate relatives to meas-
ure BP using the electronic monitor and document read-
ings on a card provided by the study team. Auxiliary
nurses will review the patient card and document mean
home BP-readings during the health coaching sessions,
which the care team will use to guide hypertension man-
agement decisions. Home BP monitoring is not part of
usual hypertensive care.
Blood pressure audit and feedback
Auxiliary nurses create lists of hypertensive patients doc-
umenting their anti-hypertensive medications, adverse
events, and their controlled or uncontrolled status.
Then, auxiliary nurses take these lists to collaborative
team meetings, where the group reviews cases and
makes management decisions following the standardized
hypertension treatment protocol. Given that usual
hypertensive care does not include completion of patient
charts, the study team is providing paper-based forms
for auxiliary nurses to generate the lists of patients with
hypertension. Blood pressure audit and feedback is not
included in usual hypertensive care.
Enhanced usual hypertensive care
Healthcare providers based at the control health dis-
tricts will receive a one-morning, 4-h training session
on the Ministry of Health Healthcare Norms 2018 for
hypertension management, conducted by Ministry of
Health representatives. Similar to the intervention
arm, the study will provide one electronic BP monitor
(Omron HEM-7121) to each health center and health
post. At the central government and department
levels, the study team will work with Ministry of
Health officials to promote the purchase, distribution
and availability of essential hypertensive medications
at participating health districts at a minimum. While
participants in the intervention group receive an elec-
tronic BP monitor (Omron HEM-7121) at the first
study visit, those in the control arm will receive the
BP monitor and study-specific educational materials
at the last study visit.
Outcomes
The primary clinical outcome is the 18-month difference
in the proportion of participants with controlled hyper-
tension (BP < 130/80 mmHg) between the intervention
and control groups. The secondary clinical outcome is
the 18-month net change in systolic and diastolic BP
from baseline. The BP measurement for inclusion in the
study and used in the outcome analysis will be standard-
ized following the AHA guidelines and conducted by
trained study staff [22, 25]. The clinical outcomes cor-
respond to intervention effectiveness, measured at the
individual participant level. We will also measure imple-
mentation outcomes as part of the second co-primary
aim. The context-enhanced Reach, Efficacy, Adoption,
Implementation, Maintenance (RE-AIM)/ Practical Ro-
bust Implementation and Sustainability Model (PRISM)
framework will guide the evaluation of the implementa-
tion at the patient, provider, and health system levels.
Using a mixed-methods approach, we will evaluate the
following implementation outcomes: acceptability, adop-
tion, feasibility, fidelity, adaptation, reach, sustainability,
and cost effectiveness [26].
Sample size and power
The power calculation for the primary outcome was
based on the following assumptions: (1) a two-sided sig-
nificance level of 0.05; (2) statistical power of 90%; (3) a
proportion of patients with BP < 130/80 mmHg of 50%
in the control group; (4) detectable group differences in
proportion of BP < 130/80 mmHg of 15% (65% of pa-
tients with BP < 130/80 mmHg in the intervention
group); (5) intra-cluster correlation (ICC) coefficient for
hypertension control of 0.055; (6) 18 clusters (health dis-
tricts) per group; and (7) 85% follow-up rate by 18
months. The sample size for each cluster is 37 based on
a two-sample Z test for individual-level comparison of a
cluster design. Further assuming an 85% follow-up rate
by 18 months, we will need to recruit 44 participants
from each district and 1584 study participants for the
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entire study. The statistical power is even higher for the
secondary outcomes because they are continuous vari-
ables. Table 1 shows the statistical power based on
various follow-up rates and ICCs. The intra-cluster cor-
relation over 18 months was based on our data from the
Hypertensive Control Program in Argentina (HCPIA)
[27, 28].
We expect that each health district will enroll at least
44 participants. Given the longstanding engagement of
Ministry of Health providers at the community level, we
anticipate being able to successfully enroll the total
number of participants. To enhance recruitment of par-
ticipants, we have engaged healthcare providers and
community leaders since the preparation phase of the
trial. In addition, healthcare providers were familiarized
with eligibility criteria and the enrollment process during
training workshops and are referring potential study par-
ticipants to study staff, who maintain constant commu-
nication with providers.
Statistical analysis plan
The primary analysis will be conducted on an
intention-to-treat basis. We will compare the propor-
tion of participants who achieve BP control in the
intervention arm and the control arm by using logis-
tic mixed-effects regression analysis, where partici-
pants and clusters are included as random effects and
the intervention group, time, and group-by-time inter-
action are included as fixed effects. In a secondary
analysis, blood pressure values at baseline, 6 months,
12 months, and 18 months will be modeled in a linear
mixed-effects regression analysis. Pre-defined sub-
group analyses by age (< 60 vs. ≥ 60 years), sex (men
vs. women), history of cardiovascular disease (CVD)
(yes vs. no), and body mass index (< 30 vs. ≥ 30 kg/
m2) will be conducted. Further details of the data
management, statistical methods, and quality control
plans are available upon request from the authors.
Implementation evaluation
We will use the context-enhanced RE-AIM/PRISM
framework to evaluate the implementation of the multi-
component program [29, 30]. The implementation
evaluation will allow us to monitor and improve pro-
gram implementation, understand the relationship be-
tween implementation characteristics and health
outcomes, and design the dissemination plan if the pro-
gram is proven effective. We will assess the expanded
RE-AIM/PRISM dimensions at the patient, provider, and
health system levels (See Table 2).
In addition to the five dimensions of RE-AIM (reach,
effectiveness, adoption, implementation and mainten-
ance) we will assess the program fit and sustainability in-
frastructure of PRISM [31]. The implementation
outcomes that we will measure are: acceptability, adop-
tion, feasibility, fidelity, adaptation, reach, sustainability,
and cost effectiveness [26].
We will use a combination of quantitative and qualita-
tive methods to assess the domains of interest. We will
gather data during patients’ study visits at 6, 12, and 18
months. In addition, we will make regular (1–2 months)
visits to healthcare facilities to capture study inputs and
ongoing program implementation captured in checklists.
In a subset of study sites, we will conduct interviews
with participants and family members, providers, and
public health administrators using semi-structured inter-
view guides combined with chart-stimulated recall, sha-
dowing, and direct observation.
Cost-effectiveness analysis
We will perform a cost-effectiveness analysis using the
individual patient data collected at follow-up visits (see
Fig. 3), expressed as incremental cost per additional per-
centage of patients that achieved hypertension control at
18 months. Intervention costs will include fixed costs
such as education of health providers and salary of auxil-
iary nurses, and variable costs such as electronic BP
monitors. Healthcare costs will include ambulatory costs,
such as drugs and laboratory tests, and hospital care
(hospitalization). Protocol-driven costs will be excluded.
We will analyze differences in costs following a similar
analytical approach as that used for estimating health
outcomes [32]. Uncertainty around the incremental
cost-effectiveness ratio (ICER) will be estimated by boot-
strapping techniques, and a 95% credible interval will be
reported [33, 34].
Discussion
This is the first randomized cluster trial in Central Amer-
ica to test the effect of a multicomponent intervention
program for BP control in underserved rural populations.
The intervention and study outcomes are patient-











0.050 0.055 0.060 0.065 0.070 0.075
80% 1260/35 0.9132 0.8961 0.8791 0.8614 0.8434 0.8524
81% 1296/36 0.9154 0.8987 0.8821 0.8631 0.8453 0.8275
83% 1332/37 0.9176 0.9013 0.8836 0.8665 0.8490 0.8295
85% 1368/38 0.9197 0.9038 0.8865 0.8681 0.8508 0.8336
a = 0.05, control rate in control group = 50%, difference in control rate
between intervention and control groups = 15%, total sample
size = 1584 participants
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centered, and patients, Ministry of Health provider-teams,
and other stakeholders have been engaged at every step of
the proposed study. The multicomponent intervention
program is designed to address barriers at the healthcare
system, provider-team, and patient levels. The proposed
study will generate urgently needed data on effective,
adoptable, and sustainable intervention strategies aimed at
reducing BP-related disease burden in Central America
and other low-income settings.
Although the efficacy and effectiveness of lifestyle
modifications and antihypertensive drug treatment on
the prevention of HTN and consequent CVD risk have
been demonstrated in randomized controlled trials, this
knowledge has not been fully applied in LMIC [35, 36].
The proposed study will test whether an evidence-based,
multilevel and multicomponent intervention program
can be translated to and is feasible in the primary health-
care systems of this region.
We will disseminate the study findings, promote scale
up, and scale out of the program, if proven effective.
This study will generate urgently needed data on effect-
ive, adoptable, and sustainable intervention and imple-
mentation strategies to improve hypertension control in
Guatemala and other low- and middle-income countries.
Trial status
A stakeholder engagement process and needs assessment are
finalized. The study manual of operations was developed and
training of study staff has been completed. The Data Safety
and Monitoring Board met twice during 2019: prior to study
enrollment and during the first semester of enrollment. Inter-
vention educational materials for healthcare providers and pa-
tients were adapted and finalized. Training workshops and
field certifications of healthcare providers were developed and
completed. The Community Advisory Board was formed
with local healthcare providers and hypertensive patients and
has met twice. Enrollment into the study began in July 2019
and 89% was completed by March 20th 2020. Enrollment has
been paused due to COVID-19 and will reinitiate as soon as
Table 2 Implementation evaluation
RE-AIM/ PRISM
dimension
Patient level Healthcare provider (HCP) level System level




Effectiveness See Fig. 3
Adoption Number of HCPs who participate in training
sessions/total HCPs
Representativeness of HCPs who participate in
training sessions
Number of health districts, health
centers and posts that participate in
training sessions/total
Representativeness of health districts




Documentation of home-based BP
measurement on patient’s card
Number of health coaching sessions
received
Characteristics of training workshops for HCPs
Application of HTN algorithm by HCP
Extent to which implementation strategies
(patient lists, audit and feedback, collaborative
team meetings, supervision, and coaching
sessions) are implemented
Specific modes of implementation by different
providers
Types and frequency of delivery adaptation
made
Availability of intervention inputs:
medications, monitors, materials, staff




Sustained BP control, medication
adherence, lifestyle changes, quality
of life, stages of behavior change at
18months
Sustained HTN knowledge over time
Intention to continue implementation beyond
study period
Adaptations needed in order to continue
implementation
Intention to continue beyond study
period
Adaptations needed in order to continue
implementation
Fit Adaptations by healthcare providers to make
the intervention and implementation
strategies fit to their context
Changes at the national, state and health
district level to be able to implement








Support and resources from MOH





HTN hypertension, BP blood pressure, MOH Ministry of Health
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national policies allow. This is study protocol version 6.1 and
the version date is 21 May 2019.
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